Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Nauck, J. Meier, M. Cavender, Mirna Aziz, D. Drucker (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 InhibitorsCirculation, 136
F. Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Y. Zhang, Xiaochi Quan, L. Ji, S. Zhan (2015)
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.Diabetes research and clinical practice, 110 1
A. Colosia, R. Palencia, Shahnaz Khan (2013)
Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature reviewDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 6
S. Ogawa, M. Ishiki, Kazuhiro Nako, Masashi Okamura, Miho Senda, Takefumi Mori, S. Ito (2011)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.The Tohoku journal of experimental medicine, 223 2
D. Drucker (2006)
The biology of incretin hormones.Cell metabolism, 3 3
S. Inzucchi, B. Zinman, D. Fitchett, C. Wanner, E. Ferrannini, M. Schumacher, C. Schmoor, K. Ohneberg, O. Johansen, J. George, S. Hantel, E. Bluhmki, J. Lachin (2017)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialDiabetes Care, 41
G. Mistry, A. Maes, K. Lasseter, M. Davies, K. Gottesdiener, J. Wagner, G. Herman (2008)
Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate HypertensionThe Journal of Clinical Pharmacology, 48
K. Kaku, H. Watada, Y. Iwamoto, K. Utsunomiya, Y. Terauchi, K. Tobe, Y. Tanizawa, E. Araki, M. Ueda, H. Suganami, D. Watanabe (2014)
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative studyCardiovascular Diabetology, 13
R. Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, U. Vijapurkar, C. Damaraju, M. Pfeifer (2016)
Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and HypertensionThe Journal of Clinical Hypertension, 18
A. El-Naggar, Dalia Zaafar, Mohammed Elyamany, S. Hassanin, Atef Bassyouni, H. Abdel-Latif (2019)
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive PatientsJournal of Cardiovascular Pharmacology and Therapeutics, 24
Munehiro Kitada, Shin-ichi Tsuda, K. Konishi, Ai Takeda-Watanabe, M. Fujii, K. Kanasaki, M. Nishizawa, A. Nakagawa, D. Koya (2017)
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent mannerBMJ Open Diabetes Research & Care, 5
Jie Liu, A. Pong, Silvina Gallo, A. Darekar, S. Terra (2019)
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trialsCardiovascular Diabetology, 18
I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali, U. Broedl, H. Woerle (2014)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and HypertensionDiabetes Care, 38
K. Kario, K. Okada, Mitsutoshi Kato, M. Nishizawa, Tetsuro Yoshida, T. Asano, Kazuaki Uchiyama, Y. Niijima, T. Katsuya, H. Urata, J. Osuga, T. Fujiwara, Shoji Yamazaki, N. Tomitani, Hiroshi Kanegae (2018)
Twenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal HypertensionCirculation, 139
A. Scheen (2014)
Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 DiabetesClinical Pharmacokinetics, 54
E. Sanidas, M. Velliou, D. Papadopoulos, A. Fotsali, D. Iliopoulos, M. Mantzourani, K. Toutouzas, J. Barbetseas (2020)
Antihypertensive Drugs and Risk of Cancer. Between Scylla and Charybdis.American journal of hypertension
B. Zinman, C. Wanner, J. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. Johansen, H. Woerle, U. Broedl, S. Inzucchi (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.The New England journal of medicine, 373 22
B. Scirica, Deepak Bhatt, E. Braunwald, P. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S. Wiviott, Elaine Hoffman, M. Cavender, J. Udell, N. Desai, Ofri Mosenzon, Darren Mcguire, K. Ray, Lawrence Leiter, I. Raz (2013)
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.The New England journal of medicine, 369 14
C. Sjöström, P. Johansson, A. Ptaszynska, J. List, E. Johnsson (2015)
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetesDiabetes & Vascular Disease Research, 12
Yoojin Kim, A. Babu (2012)
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetesDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 5
M. Mazidi, P. Rezaie, Hong‐kai Gao, A. Kengne (2017)
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 PatientsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
E. Sanidas, D. Papadopoulos, E. Hatziagelaki, C. Grassos, M. Velliou, J. Barbetseas (2019)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.American journal of hypertension
Whitney Saulsberry, Craig Coleman, Elizabeth Mearns, E. Zaccaro, Y. Doleh, D. Sobieraj (2015)
Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetesInternational Journal of Clinical Practice, 69
B. Neal, V. Perkovic, K. Mahaffey, D. Zeeuw, G. Fulcher, N. Erondu, Wayne Shaw, G. Law, Mehul Desai, D. Matthews (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 377
Feliciano Chanana, Paquissi, Valdano Manuel, Ana Manuel, Guiomar Mateus, Bruna David, Gertrudes Béu, A. Castela
Vascular Health and Risk Management Dovepress Prevalence of Cardiovascular Risk Factors among Workers at a Private Tertiary Center in Angola
R. Guthrie (2018)
Canagliflozin and cardiovascular and renal events in type 2 diabetesPostgraduate Medicine, 130
Yoshiaki Kubota, M. Miyamoto, G. Takagi, Takeshi Ikeda, Sonoko Kirinoki-Ichikawa, Kotoko Tanaka, K. Mizuno (2012)
The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 DiabetesJournal of Korean Medical Science, 27
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Kato, A. Cahn, Michael Silverman, Thomas Zelniker, J. Kuder, S. Murphy, Deepak Bhatt, Lawrence Leiter, Darren Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 380
M. Weber, T. Mansfield, Federica Alessi, N. Iqbal, S. Parikh, A. Ptaszynska (2016)
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockadeBlood Pressure, 25
Michael Cobble, R. Frederich (2012)
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataCardiovascular Diabetology, 11
Yosuke Takamiya, K. Okamura, K. Shirai, Tetsu Okuda, Kunihisa Kobayashi, H. Urata (2019)
Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T)Clinical and Experimental Hypertension, 42
L. Cosenso-Martin, L. Giollo-Junior, J. Vilela-Martin (2015)
DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive PatientMedicine, 94
Tetsuhiro Tanaka, M. Nangaku, A. Nishiyama (2011)
The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitorsCurrent Opinion in Nephrology and Hypertension, 20
C. Bailey, J. Gross, A. Pieters, A. Bastien, J. List (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 375
DS Hsia (2017)
73Curr Opin Endocrinol Diabetes Obes, 24
Wook Kim, Josephine Egan (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes TreatmentPharmacological Reviews, 60
M. Weber, T. Mansfield, V. Cain, N. Iqbal, S. Parikh, A. Ptaszynska (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.The lancet. Diabetes & endocrinology, 4 3
W. Baker, L. Buckley, Michael Kelly, John Bucheit, Eric Parod, Roy Brown, S. Carbone, A. Abbate, Dave Dixon (2017)
Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
Bin Wang, J. Zhong, H. Lin, Zhigang Zhao, Zhencheng Yan, Hong-bo He, Yinxing Ni, Daoyan Liu, Zhiming Zhu (2013)
Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, 15
D. Drucker, M. Nauck (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 368
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren, V. Woo, O. Hansen, A. Holst, Jonas Pettersson, T. Vilsbøll (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine, 375 19
W. White, C. Cannon, S. Heller, S. Nissen, R. Bergenstal, G. Bakris, Alfonso Perez, P. Fleck, C. Mehta, S. Kupfer, Craig Wilson, W. Cushman, F. Zannad (2013)
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.The New England journal of medicine, 369 14
Niren Shah, W. Deeb, R. Choksi, B. Epstein (2012)
Dapagliflozin: A Novel Sodium‐Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 32
M. Olmo-García, J. Merino-Torres (2018)
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 DiabetesJournal of Diabetes Research, 2018
S. Jabbour, J. Frias, C. Guja, É. Hardy, A. Ahmed, P. Öhman (2018)
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 studyDiabetes, Obesity & Metabolism, 20
Shouhei Yuasa, Kazuyoshi Sato, Takamoto Furuki, K. Minamizawa, H. Sakai, Y. Numata, Keiichi Chin, Jisho Kojima, M. Miyakawa, I. Matsuba (2017)
Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 DiabetesJournal of Clinical Medicine Research, 9
Anushka Patel (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 370
A. Scheen (2018)
Cardiovascular Effects of New Oral Glucose-Lowering AgentsCirculation Research, 122
P. Schlatter, C. Beglinger, J. Drewe, H. Gutmann (2007)
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cellsRegulatory Peptides, 141
G. Lozano-Ortega, S. Goring, H. Bennett, K. Bergenheim, C. Sternhufvud, J. Mukherjee (2016)
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylureaCurrent Medical Research and Opinion, 32
W. White, Craig Wilson, G. Bakris, R. Bergenstal, C. Cannon, W. Cushman, S. Heller, C. Mehta, S. Nissen, F. Zannad, S. Kupfer (2016)
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinHypertension, 68
M. Husain, A. Birkenfeld, M. Donsmark, K. Dungan, F. Eliaschewitz, D. Franco, Ole Jeppesen, I. Lingvay, Ofri Mosenzon, S. Pedersen, C. Tack, M. Thomsen, T. Vilsbøll, M. Warren, S. Bain (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine
Xiaodan Zhang, Qingyu Zhao (2016)
Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysisJournal of Hypertension, 34
WL Baker (2014)
e9J Am Soc Hypertens, 8
J. McMurray, S. Solomon, S. Inzucchi, L. Køber, M. Kosiborod, F. Martinez, P. Ponikowski, M. Sabatine, I. Anand, J. Bělohlávek, M. Böhm, C. Chiang, V. Chopra, R. Boer, Akshay Desai, M. Diez, J. Drożdż, A. Dukát, J. Ge, J. Howlett, T. Katova, M. Kitakaze, C. Ljungman, B. Merkely, J. Nicolau, E. O’Meara, M. Petrie, P. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D. DeMets, K. Docherty, P. Jhund, O. Bengtsson, M. Sjöstrand, A. Langkilde, Modele Ogunniyi (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.The New England journal of medicine
Jennifer Green, M. Bethel, P. Armstrong, J. Buse, S. Engel, Jyotsna Garg, R. Josse, K. Kaufman, J. Koglin, S. Korn, J. Lachin, Darren Mcguire, M. Pencina, E. Standl, P. Stein, S. Suryawanshi, F. Werf, E. Peterson, R. Holman (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine, 373 3
Y Kim (2012)
313Diabetes Metab Syndr Obes, 5
T. Filippatos, V. Tsimihodimos, M. Elisaf (2016)
Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitorsExpert Opinion on Pharmacotherapy, 17
T. Okerson, P. Yan, A. Stonehouse, R. Brodows (2010)
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.American journal of hypertension, 23 3
Y. Seino, Takashi Sasaki, A. Fukatsu, M. Ubukata, S. Sakai, Y. Samukawa (2014)
Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 studyCurrent Medical Research and Opinion, 30
K. Han, S. Chon, C. Chung, Soo Lim, K. Lee, S. Baik, C. Jung, Dong-Sun Kim, K. Park, K. Yoon, In-Kyu Lee, B. Cha, Taishi Sakatani, Sumi Park, Moon-Kyu Lee (2018)
Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trialDiabetes, Obesity & Metabolism, 20
D. Russell-Jones, A. Vaag, O. Schmitz, B. Sethi, N. Lalic, S. Antic, M. Zdravkovic, G. Ravn, R. Simó, on Group (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia, 52
S. Kishimoto, Y. Kinoshita, Takeshi Matsumoto, T. Maruhashi, M. Kajikawa, Shogo Matsui, Haruki Hashimoto, Yuji Takaeko, Y. Kihara, K. Chayama, Chikara Goto, F. Yusoff, A. Nakashima, K. Noma, Y. Higashi (2019)
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.American journal of hypertension, 32 7
A. Goud, Jixin Zhong, M. Peters, R. Brook, S. Rajagopalan (2016)
GLP-1 Agonists and Blood Pressure: A Review of the EvidenceCurrent Hypertension Reports, 18
G. Mancia, C. Cannon, I. Tikkanen, C. Zeller, L. Ley, H. Woerle, U. Broedl, O. Johansen (2016)
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationHypertension, 68
S. Brunton (2014)
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?International Journal of Clinical Practice, 68
Elizabeth Mearns, D. Sobieraj, C. White, Whitney Saulsberry, C. Kohn, Y. Doleh, E. Zaccaro, C. Coleman (2015)
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-AnalysisPLoS ONE, 10
J. Gutzwiller, Stefan Tschopp, A. Bock, C. Zehnder, A. Huber, Monika Kreyenbuehl, H. Gutmann, J. Drewe, C. Henzen, B. Goeke, C. Beglinger (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.The Journal of clinical endocrinology and metabolism, 89 6
Mohammad Katout, Hong Zhu, Jessica Rutsky, Parthy Shah, R. Brook, Jixin Zhong, S. Rajagopalan (2014)
Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.American journal of hypertension, 27 1
T. Rieg, Maria Gerasimova, F. Murray, T. Masuda, T. Tang, Michael Rose, D. Drucker, V. Vallon (2012)
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.American journal of physiology. Renal physiology, 303 7
A. Basu, N. Charkoudian, W. Schrage, R. Rizza, R. Basu, M. Joyner (2007)
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.American journal of physiology. Endocrinology and metabolism, 293 5
M. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. Gerstein, L. Køber, Francesca Lawson, Lin Ping, Xiaodan Wei, E. Lewis, A. Maggioni, J. McMurray, J. Probstfield, M. Riddle, S. Solomon, J. Tardif (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.The New England journal of medicine, 373 23
A. Liakos, T. Karagiannis, Eleni Athanasiadou, M. Sarigianni, M. Mainou, K. Papatheodorou, E. Bekiari, A. Tsapas (2014)
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysisDiabetes, 16
W. Baker, Lindsay Smyth, D. Riche, Emily Bourret, K. Chamberlin, W. White (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.Journal of the American Society of Hypertension : JASH, 8 4
MI Del Olmo-Garcia (2018)
4020492J Diabetes Res, 2018
Y. Kanai, W. Lee, G. You, Dennis Brown, M. Hediger (1994)
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.The Journal of clinical investigation, 93 1
D. Hsia, Owen Grove, W. Cefalu (2016)
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitusCurrent Opinion in Endocrinology & Diabetes and Obesity, 24
JW Reed (2016)
393Vasc Health Risk Manag, 12
S. Marso, Gilbert Daniels, K. Brown-Frandsen, Peter Kristensen, Johannes Mann, Michael Nauck, Steven Nissen, Stuart Pocock, Neil Poulter, Lasse Ravn, William Steinberg, M. Stockner, B. Zinman, R. Bergenstal, J. Buse (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.The New England journal of medicine, 375 4
W. Washburn, S. Poucher (2013)
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitusExpert Opinion on Investigational Drugs, 22
Diana Röhrborn, Nina Wronkowitz, J. Eckel (2015)
DPP4 in DiabetesFrontiers in Immunology, 6
Carol Moreno, M. Mistry, R. Roman (2002)
Renal effects of glucagon-like peptide in rats.European journal of pharmacology, 434 3
M. Eynatten, Y. Gong, A. Emser, H. Woerle (2013)
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsCardiovascular Diabetology, 12
A. Scheen (2015)
A review of gliptins for 2014Expert Opinion on Pharmacotherapy, 16
Michael Grimm, Jenny Han, C. Weaver, Peter Griffin, Christine Schulteis, Haiying Dong, Jaret Malloy (2013)
Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION TrialsPostgraduate Medicine, 125
Zubair Shah, C. Pineda, Thomas Kampfrath, A. Maiseyeu, Z. Ying, Ira Racoma, J. Deiuliis, Xiaohua Xu, Qinghua Sun, S. Moffatt-Bruce, F. Villamena, S. Rajagopalan (2011)
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.Vascular pharmacology, 55 1-3
R. Holman, A. Bethel, R. Mentz, Vivian Thompson, Y. Lokhnygina, J. Buse, J. Chan, Jasmine Choi, S. Gustavson, N. Iqbal, A. Maggioni, S. Marso, P. Öhman, N. Pagidipati, N. Poulter, Ambady Ramachandran, B. Zinman, Adrian Hernandez (2017)
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 377
M. Evans, A. Schweizer, J. Foley (2016)
Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitusVascular Health and Risk Management, 12
K. Ferdinand, W. White, D. Calhoun, E. Lonn, P. Sager, R. Brunelle, Honghua Jiang, R. Threlkeld, K. Robertson, M. Geiger (2014)
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes MellitusHypertension, 64
R. DeFronzo, L. Norton, M. Abdul-Ghani (2017)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionNature Reviews Nephrology, 13
F. Cosentino, P. Grant, V. Aboyans, Clifford Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D. Grobbee, T. Hansen, H. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L. Mellbin, C. Östgren, B. Rocca, M. Roffi, Naveed Sattar, Petar Seferovic, M. Sousa‐Uva, P. Valensi, D. Wheeler, Massimo Piepoli, K. Birkeland, S. Adamopoulos, R. Ajjan, A. Avogaro, C. Baigent, M. Brodmann, H. Bueno, C. Ceconi, O. Chioncel, A. Coats, Jean-Philippe Collet, P. Collins, B. Cosyns, Carlo Mario, Miles Fisher, D. Fitzsimons, S. Halvorsen, D. Hansen, A. Hoes, R.I.G. Holt, P. Home, H. Katus, K. Khunti, M. Komajda, E. Lambrinou, U. Landmesser, B. Lewis, C. Linde, R. Lorusso, F. Mach, C. Mueller, Franz Neumann, F. Persson, S. Petersen, A. Petronio, D. Richter, G. Rosano, Peter Rossing, L. Rydén, Evgeny Shlyakhto, I. Simpson, R. Touyz, W. Wijns, M. Wilhelm, Bryan Williams (2020)
Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD)Revista Española de Cardiología
L. Duvnjak, K. Blaslov (2016)
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitusDiabetology & Metabolic Syndrome, 8
F Cosentino (2020)
255Eur Heart J., 41
G. Maliha, R. Townsend (2015)
SGLT2 inhibitors: their potential reduction in blood pressure.Journal of the American Society of Hypertension : JASH, 9 1
The prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When DM and hypertension coexist, they constitute a dual cardiovascular threat and should be adequately controlled. Novel antihyperglycemic agents, including sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been used in the treatment of DM. Beyond their glucose-lowering effects, these drugs have shown beneficial pleiotropic cardiovascular effects, including lowering of arterial blood pressure (BP), as acknowledged in the 2019 European Society of Cardiology/European Association for the Study of Diabetes guidelines on diabetes, prediabetes, and cardiovascular diseases. The purpose of this review was to summarize the available information on the BP-reducing effects of these new glucose-lowering drug classes and provide a brief report on underlying pathophysiological mechanisms. We also compare the three drug classes (SGLT-2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors) in terms of their BP-lowering effect and show that the greater BP reduction seems to be achieved with SGLT-2 inhibitors, whereas DPP-4 inhibitors have probably the mildest antihypertensive effect.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 11, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.